Time to initiate randomized controlled clinical trials with methadone in cancer patients [version 2; peer review: 2 approved]
Autor: | Hans-Joachim Kremer |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | F1000Research, Vol 8 (2022) |
Druh dokumentu: | article |
ISSN: | 2046-1402 |
DOI: | 10.12688/f1000research.20454.2 |
Popis: | Public media coverage has fueled a demand for methadone as potential cure for cancer itself. Because patients have asked for respective prescriptions, clinical societies issued statements warning against the use of methadone as long as preclinical findings have not been supported by clinical evidence. In fact, not all preclinical data clearly support relevant effects. However, strong epidemiologic data suggest beneficial effects of methadone on cancer. Alternative explanations, namely better safety of methadone or hidden selection bias, seem less likely. This uncertainty can only be resolved by randomized controlled clinical trials. This review discusses all relevant data pertinent to methadone and cancer, uncovers supportive epidemiologic data, and suggests possible study designs. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |
načítá se...